Sorafenib

Sorafenib is the active ingredient in the medication.It is available in different formulations, including tablets and capsules.

Sorafenib is used to treat advanced kidney cancer (renal cell carcinoma) that has spread to other parts of the body.

It's also used to treat advanced liver cancer (hepatocellular carcinoma) in adults who cannot have surgery or who have had surgery but the cancer has returned.

Mapsonib 200mg Tablet (Sorafenib) is a type of medicine called a kinase inhibitor. It works by blocking the action of certain enzymes that are involved in the growth and spread of cancer cells.

Store Sorafenib at room temperature, away from light and moisture.

The dosage of Sorafenib will vary depending on your condition and medical history.

Your doctor will determine the right dosage for you.

It's usually taken by mouth, with or without food.

Common side effects of Sorafenib include: hand-foot skin reaction (redness, swelling, pain, or blistering of the palms of the hands or soles of the feet)

diarrhea

high blood pressure

fatigue

hair loss

nausea

vomiting

loss of appetite

rash

mouth sores

weakness

cough

shortness of breath

fever

muscle or joint pain

blood in the urine

bleeding gums

increased bleeding

liver problems

heart problems

thyroid problems

Alcohol Consumption

It's best to avoid alcohol while taking Sorafenib, as it may increase the risk of side effects.



While Driving or operating Machinery

Sorafenib may cause dizziness or fatigue, so be cautious when driving or operating machinery.



Pregnant & Breastfeeding Women

Sorafenib is known to be harmful to the fetus. It's not recommended for pregnant or breastfeeding women.



Children

Sorafenib is not approved for use in children.



Kidney

Sorafenib may affect kidney function. Your doctor will monitor your kidney function while you're taking this medicine.



Liver

Sorafenib may affect liver function. Your doctor will monitor your liver function while you're taking this medicine.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021667s016lbl.pdf

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/sorafenib